Zura Bio Limited (ZURA)
After hours:
| Previous close | 4.6200 |
| Open | 4.6300 |
| Bid | 4.6600 x 400 |
| Ask | 4.7200 x 400 |
| Day's range | 4.5200 - 4.8400 |
| 52-week range | 2.0000 - 14.0000 |
| Volume | |
| Avg. volume | 317,383 |
| Market cap | 292.309M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
GuruFocus.comDirector Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
Director Amit Munshi has recently increased his stake in Zura Bio Ltd (NASDAQ:ZURA) by purchasing 159,744 shares of the company, as per the SEC Filing dated 2024-04-22.
Business WireZura Bio Announces Oversubscribed $112.5 Million Private Placement
HENDERSON, Nev., April 18, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the "Private Placement").
Business WireZura Bio Announces Robert Lisicki as CEO and Director
HENDERSON, Nev., April 08, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio. The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process with Founding CEO, Dr. Someit Sidhu. This transition marks a key
